{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:26:03Z","timestamp":1790400363771,"version":"4.1.0"},"reference-count":94,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T00:00:00Z","timestamp":1545436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>As patients with inflammatory bowel disease (IBD) are living longer and our medical armamentarium expands, gastroenterologists are more frequently faced with treatment decisions about patients with IBD who also have a history of malignancy. This review aims to summarize the current literature on IBD, the inherent risk of developing gastrointestinal and extra-intestinal malignancies, and the risk of malignancies associated with available biologic and immunomodulatory therapies and to discuss the overall treatment strategy for a patient with a history of malignancy.<\/jats:p>","DOI":"10.1093\/ibd\/izy376","type":"journal-article","created":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T09:38:14Z","timestamp":1545471494000},"page":"998-1005","source":"Crossref","is-referenced-by-count":14,"title":["The Treatment of Inflammatory Bowel Disease in Patients With a History of Malignancy"],"prefix":"10.1093","volume":"25","author":[{"given":"Steven C","family":"Lin","sequence":"first","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Goldowsky","sequence":"additional","affiliation":[{"name":"Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Papamichael","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S","family":"Cheifetz","sequence":"additional","affiliation":[{"name":"Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,12,22]]},"reference":[{"key":"2020071803562748700_CIT0001","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/JIR.S65979","article-title":"Inflammatory bowel disease: clinical aspects and treatments","volume":"7","author":"Fakhoury","year":"2014","journal-title":"J Inflamm Res."},{"key":"2020071803562748700_CIT0002","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJMra1403718","article-title":"Cancers complicating inflammatory bowel disease","volume":"372","author":"Beaugerie","year":"2015","journal-title":"N Engl J Med."},{"key":"2020071803562748700_CIT0003","first-page":"704","article-title":"Update on the incidence and prevalence of inflammatory bowel disease in the United States","volume":"12","author":"Loftus","year":"2016","journal-title":"Gastroenterol Hepatol (N Y)."},{"key":"2020071803562748700_CIT0004","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","article-title":"Epidemiology and natural history of inflammatory bowel diseases","volume":"140","author":"Cosnes","year":"2011","journal-title":"Gastroenterology."},{"key":"2020071803562748700_CIT0005","volume-title":"An Aging Nation: The Older Population in the United States","author":"Ortman","year":"2014"},{"key":"2020071803562748700_CIT0006","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4292\/wjgpt.v7.i1.51","article-title":"Elderly patients and inflammatory bowel disease","volume":"7","author":"Nimmons","year":"2016","journal-title":"World J Gastrointest Pharmacol Ther."},{"key":"2020071803562748700_CIT0007","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40266-017-0498-y","article-title":"Risk of malignancy in a nationwide cohort of elderly inflammatory bowel disease patients","volume":"34","author":"Khan","year":"2017","journal-title":"Drugs Aging."},{"key":"2020071803562748700_CIT0008","volume-title":"US Cancer Statistics: 1999\u20132009 incidence and Mortality Web-Based Report","author":"US Cancer Statistics Working Group","year":"2013"},{"key":"2020071803562748700_CIT0009","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European evidence-based consensus: inflammatory bowel disease and malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"J Crohns Colitis."},{"key":"2020071803562748700_CIT0010","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/ajg.2009.760","article-title":"Risk of extra-intestinal cancer in inflammatory bowel disease: meta-analysis of population-based cohort studies","volume":"105","author":"Pedersen","year":"2010","journal-title":"Am J Gastroenterol."},{"key":"2020071803562748700_CIT0011","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/00007890-199304000-00011","article-title":"The effect of immunosuppression on pre-existing cancers","volume":"55","author":"Penn","year":"1993","journal-title":"Transplantation."},{"key":"2020071803562748700_CIT0012","doi-asserted-by":"crossref","first-page":"9872","DOI":"10.3748\/wjg.v20.i29.9872","article-title":"Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis","volume":"20","author":"Kim","year":"2014","journal-title":"World J Gastroenterol."},{"key":"2020071803562748700_CIT0013","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/MIB.0b013e31828029c0","article-title":"Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies","volume":"19","author":"Lutgens","year":"2013","journal-title":"Inflamm Bowel Dis."},{"key":"2020071803562748700_CIT0014","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1111\/j.1572-0241.2005.00287.x","article-title":"Increased risk of intestinal cancer in Crohn\u2019s disease: a meta-analysis of population-based cohort studies","volume":"100","author":"Jess","year":"2005","journal-title":"Am J Gastroenterol."},{"key":"2020071803562748700_CIT0015","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2012.01.010","article-title":"Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies","volume":"10","author":"Jess","year":"2012","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2020071803562748700_CIT0016","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1007\/s11605-010-1402-9","article-title":"Intestinal cancer risk in Crohn\u2019s disease: a meta-analysis","volume":"15","author":"Laukoetter","year":"2011","journal-title":"J Gastrointest Surg."},{"key":"2020071803562748700_CIT0017","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.crohns.2013.04.009","article-title":"Non-colorectal intestinal tract carcinomas in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (II)","volume":"8","author":"Egan","year":"2014","journal-title":"J Crohns Colitis."},{"key":"2020071803562748700_CIT0018","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/bjs.5811","article-title":"Systematic review of dysplasia after restorative proctocolectomy for ulcerative colitis","volume":"94","author":"Scarpa","year":"2007","journal-title":"Br J Surg."},{"key":"2020071803562748700_CIT0019","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.gastro.2013.09.047","article-title":"Prior colorectal neoplasia is associated with increased risk of ileoanal pouch neoplasia in patients with inflammatory bowel disease","volume":"146","author":"Derikx","year":"2014","journal-title":"Gastroenterology."},{"key":"2020071803562748700_CIT0020","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.cgh.2013.11.007","article-title":"Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease","volume":"12","author":"Castro","year":"2014","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2020071803562748700_CIT0021","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.cgh.2007.05.020","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study","volume":"5","author":"Welzel","year":"2007","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2020071803562748700_CIT0022","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/ajg.2013.249","article-title":"Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study","volume":"108","author":"Jess","year":"2013","journal-title":"Am J Gastroenterol."},{"key":"2020071803562748700_CIT0023","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1038\/ajg.2017.96","article-title":"Extracolonic cancer in inflammatory bowel disease: data from the GETECCU Eneida Registry","volume":"112","author":"Chaparro","year":"2017","journal-title":"Am J Gastroenterol."},{"key":"2020071803562748700_CIT0024","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/gut.2004.051771","article-title":"Risk of haematopoietic cancer in patients with inflammatory bowel disease","volume":"54","author":"Askling","year":"2005","journal-title":"Gut."},{"key":"2020071803562748700_CIT0025","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease: a population-based study","volume":"91","author":"Bernstein","year":"2001","journal-title":"Cancer."},{"key":"2020071803562748700_CIT0026","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.crohns.2013.04.006","article-title":"Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III)","volume":"8","author":"Magro","year":"2014","journal-title":"J Crohns Colitis."},{"key":"2020071803562748700_CIT0027","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/sj.bjc.6604935","article-title":"Risks of myeloid malignancies in patients with autoimmune conditions","volume":"100","author":"Anderson","year":"2009","journal-title":"Br J Cancer."},{"key":"2020071803562748700_CIT0028","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease","volume":"8","author":"Long","year":"2010","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2020071803562748700_CIT0029","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology."},{"key":"2020071803562748700_CIT0030","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology."},{"key":"2020071803562748700_CIT0031","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/ecco-jcc\/jjv032","article-title":"Incidence, management, and course of cancer in patients with inflammatory bowel disease","volume":"9","author":"Algaba","year":"2015","journal-title":"J Crohns Colitis."},{"key":"2020071803562748700_CIT0032","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/MIB.0000000000000338","article-title":"Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia\/cancer? A meta-analysis","volume":"21","author":"Allegretti","year":"2015","journal-title":"Inflamm Bowel Dis."},{"key":"2020071803562748700_CIT0033","doi-asserted-by":"crossref","first-page":"6167","DOI":"10.3748\/wjg.v12.i38.6167","article-title":"Abnormalities of uterine cervix in women with inflammatory bowel disease","volume":"12","author":"Bhatia","year":"2006","journal-title":"World J Gastroenterol."},{"key":"2020071803562748700_CIT0034","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cgh.2014.07.036","article-title":"Inflammatory bowel disease and cervical neoplasia: a population-based nationwide cohort study","volume":"13","author":"Rungoe","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2020071803562748700_CIT0035","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/ibd\/izx062","article-title":"Neoplasia and precursor lesions of the female genital tract in IBD: epidemiology, role of immunosuppressants, and clinical implications","volume":"24","author":"Hazenberg","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2020071803562748700_CIT0036","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.bjc.6604796","article-title":"Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin\u2019s lymphoma: a population-based case-control study","volume":"100","author":"Jensen","year":"2009","journal-title":"Br J Cancer."},{"key":"2020071803562748700_CIT0037","doi-asserted-by":"crossref","first-page":"R21","DOI":"10.1186\/bcr3106","article-title":"Use of glucocorticoids and risk of breast cancer: a Danish population-based case-control study","volume":"14","author":"S\u00f8rensen","year":"2012","journal-title":"Breast Cancer Res."},{"key":"2020071803562748700_CIT0038","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2008.10.021","article-title":"Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study","volume":"136","author":"Singh","year":"2009","journal-title":"Gastroenterology."},{"key":"2020071803562748700_CIT0039","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/S0140-6736(02)11922-2","article-title":"Effects of corticosteroid use on treatment of solid tumours","volume":"360","author":"Rutz","year":"2002","journal-title":"Lancet."},{"key":"2020071803562748700_CIT0040","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.3748\/wjg.v22.i20.4794","article-title":"Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment","volume":"22","author":"Axelrad","year":"2016","journal-title":"World J Gastroenterol."},{"key":"2020071803562748700_CIT0041","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/bmb\/ldl020","article-title":"Thiopurines, DNA damage, DNA repair and therapy-related cancer","author":"Karran","year":"2006","journal-title":"Br Med Bull."},{"key":"2020071803562748700_CIT0042","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1046\/j.1365-2036.2002.01297.x","article-title":"Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine","volume":"16","author":"Fraser","year":"2002","journal-title":"Aliment Pharmacol Ther."},{"key":"2020071803562748700_CIT0043","doi-asserted-by":"crossref","first-page":"4877","DOI":"10.3748\/wjg.v19.i30.4877","article-title":"Thiopurines related malignancies in inflammatory bowel disease: local experience in Granada, Spain","volume":"19","author":"G\u00f3mez-Garc\u00eda","year":"2013","journal-title":"World J Gastroenterol."},{"key":"2020071803562748700_CIT0044","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0140-6736(94)92150-4","article-title":"Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease","volume":"343","author":"Connell","year":"1994","journal-title":"Lancet."},{"key":"2020071803562748700_CIT0045","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1111\/j.1572-0241.1999.01530.x","article-title":"Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine","volume":"94","author":"Korelitz","year":"1999","journal-title":"Am J Gastroenterol."},{"key":"2020071803562748700_CIT0046","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/aje\/kws375","article-title":"Use of azathioprine and the risk of cancer in inflammatory bowel disease","volume":"177","author":"Pasternak","year":"2013","journal-title":"Am J Epidemiol."},{"key":"2020071803562748700_CIT0047","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/gutjnl-2013-305763","article-title":"Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer","volume":"63","author":"Beaugerie","year":"2014","journal-title":"Gut."},{"key":"2020071803562748700_CIT0048","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/ajg.2013.451","article-title":"Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis","volume":"109","author":"Ariyaratnam","year":"2014","journal-title":"Am J Gastroenterol."},{"key":"2020071803562748700_CIT0049","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet."},{"key":"2020071803562748700_CIT0050","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2020071803562748700_CIT0051","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/MIB.0000000000000457","article-title":"Risk of lymphoma, colorectal and skin cancer in patients with IBD treated with immunomodulators and biologics: a Quebec Claims Database study","volume":"21","author":"Kopylov","year":"2015","journal-title":"Inflamm Bowel Dis."},{"issue":"5","key":"2020071803562748700_CIT0052","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1053\/j.gastro.2013.09.035","article-title":"Lymphoma: the b\u00eate noire of the long-term use of thiopurines in adult and elderly patients with inflammatory bowel disease","volume":"145","author":"Beaugerie","year":"2013","journal-title":"Gastroenterology."},{"key":"2020071803562748700_CIT0053","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/ibd\/izx072","article-title":"Infliximab for Crohn\u2019s disease: more than 13 years of real-world experience","volume":"24","author":"Lichtenstein","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2020071803562748700_CIT0054","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1126\/science.1114233","article-title":"Azathioprine and UVA light generate mutagenic oxidative DNA damage","volume":"309","author":"O\u2019Donovan","year":"2005","journal-title":"Science."},{"key":"2020071803562748700_CIT0055","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ajg.2012.181","article-title":"Risk of melanoma in patients who receive thiopurines for inflammatory bowel disease is not increased","volume":"107","author":"Peyrin-Biroulet","year":"2012","journal-title":"Am J Gastroenterol."},{"key":"2020071803562748700_CIT0056","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/apt.13466","article-title":"Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"43","author":"Bourrier","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"2020071803562748700_CIT0057","doi-asserted-by":"crossref","first-page":"E711","DOI":"10.1002\/ijc.29209","article-title":"Risk of cervical cancer in women with autoimmune diseases, in relation with their use of immunosuppressants and screening: population-based cohort study","volume":"136","author":"Dugu\u00e9","year":"2015","journal-title":"Int J Cancer."},{"key":"2020071803562748700_CIT0058","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum."},{"key":"2020071803562748700_CIT0059","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V99.11.3909","article-title":"Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in france","volume":"99","author":"Mariette","year":"2002","journal-title":"Blood."},{"key":"2020071803562748700_CIT0060","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"2020071803562748700_CIT0061","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/art.23716","article-title":"Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate","volume":"59","author":"Buchbinder","year":"2008","journal-title":"Arthritis Rheum."},{"key":"2020071803562748700_CIT0062","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/annrheumdis-2016-209131","article-title":"Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"2020071803562748700_CIT0063","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"key":"2020071803562748700_CIT0064","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med."},{"issue":"4","key":"2020071803562748700_CIT0065","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/bjd.16798","article-title":"Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study","volume":"179","author":"Valenzuela","year":"2018","journal-title":"Br J Dermatol."},{"key":"2020071803562748700_CIT0066","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/acr.23421","article-title":"Lymphoma in the tofacitinib rheumatoid arthritis clinical development program","volume":"70","author":"Mariette","year":"2018","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"2020071803562748700_CIT0067","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn\u2019s disease: meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2020071803562748700_CIT0068","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/apt.12624","article-title":"Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-\u03b1 therapy in inflammatory bowel disease","volume":"39","author":"Williams","year":"2014","journal-title":"Aliment Pharmacol Ther."},{"key":"2020071803562748700_CIT0069","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"Nyboe Andersen","year":"2014","journal-title":"JAMA."},{"key":"2020071803562748700_CIT0070","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ajg.2012.89","article-title":"A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol."},{"key":"2020071803562748700_CIT0071","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1136\/annrheumdis-2017-212613","article-title":"Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors","volume":"77","author":"Beukelman","year":"2018","journal-title":"Ann Rheum Dis."},{"key":"2020071803562748700_CIT0072","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: a meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2020071803562748700_CIT0073","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1038\/ajg.2011.283","article-title":"Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease","volume":"106","author":"Herrinton","year":"2011","journal-title":"Am J Gastroenterol."},{"key":"2020071803562748700_CIT0074","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/s41395-018-0098-4","article-title":"Lymphoma risk and overall safety profile of adalimumab in patients with Crohn\u2019s disease with up to 6 years of follow-up in the pyramid registry","volume":"113","author":"D\u2019Haens","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"2020071803562748700_CIT0075","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA."},{"key":"2020071803562748700_CIT0076","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/ajg.2012.334","article-title":"T-cell non-Hodgkin\u2019s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-\u03b1) inhibitors: results of the REFURBISH study","volume":"108","author":"Deepak","year":"2012","journal-title":"Am J Gastroenterol."},{"key":"2020071803562748700_CIT0077","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-2036.2008.03766.x","article-title":"Screening differences and risk of cervical cancer in inflammatory bowel disease","volume":"28","author":"Hutfless","year":"2008","journal-title":"Aliment Pharmacol Ther."},{"key":"2020071803562748700_CIT0078","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/apt.13215","article-title":"Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease","volume":"41","author":"Luthra","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"key":"2020071803562748700_CIT0079","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1007\/s12325-016-0467-6","article-title":"Efficacy and safety of vedolizumab in ulcerative colitis and Crohn\u2019s disease patients stratified by age","volume":"34","author":"Yajnik","year":"2017","journal-title":"Adv Ther."},{"key":"2020071803562748700_CIT0080","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.14075","article-title":"Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease","volume":"46","author":"Bye","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"key":"2020071803562748700_CIT0081","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut."},{"key":"2020071803562748700_CIT0082","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.12214","article-title":"Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up","volume":"168","author":"Papp","year":"2013","journal-title":"Br J Dermatol."},{"key":"2020071803562748700_CIT0083","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jaad.2017.07.013","article-title":"Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry","volume":"77","author":"Fiorentino","year":"2017","journal-title":"J Am Acad Dermatol."},{"key":"2020071803562748700_CIT0084","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jaad.2011.06.041","article-title":"Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials","volume":"66","author":"Gordon","year":"2012","journal-title":"J Am Acad Dermatol."},{"key":"2020071803562748700_CIT0085","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med."},{"key":"2020071803562748700_CIT0086","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/apt.14487","article-title":"Long-term efficacy and safety of ustekinumab in 122 refractory Crohn\u2019s disease patients: a multicentre experience","volume":"47","author":"Wils","year":"2018","journal-title":"Aliment Pharmacol Ther."},{"key":"2020071803562748700_CIT0087","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cgh.2015.07.037","article-title":"Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents","volume":"14","author":"Axelrad","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2020071803562748700_CIT0088","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology."},{"key":"2020071803562748700_CIT0089","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamadermatol.2015.3029","article-title":"Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer","volume":"152","author":"Scott","year":"2016","journal-title":"JAMA Dermatol."},{"key":"2020071803562748700_CIT0090","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1002\/cncr.30601","article-title":"A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck","volume":"123","author":"Manyam","year":"2017","journal-title":"Cancer."},{"key":"2020071803562748700_CIT0091","first-page":"346","article-title":"Pre","volume":"3","author":"Merchen","year":"2003","journal-title":"Am J Transpl."},{"key":"2020071803562748700_CIT0092","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.crohns.2013.12.022","article-title":"Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease","volume":"8","author":"Rajca","year":"2014","journal-title":"J Crohns Colitis."},{"key":"2020071803562748700_CIT0093","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.cgh.2012.06.016","article-title":"Effects of cancer treatment on inflammatory bowel disease remission and reactivation","volume":"10","author":"Axelrad","year":"2012","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2020071803562748700_CIT0094","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1097\/MIB.0000000000000002","article-title":"Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops","volume":"20","author":"Swoger","year":"2014","journal-title":"Inflamm Bowel Dis."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/25\/6\/998\/33510233\/izy376.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ibdjournal\/article-pdf\/25\/6\/998\/33510233\/izy376.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,18]],"date-time":"2020-07-18T07:57:00Z","timestamp":1595059020000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/25\/6\/998\/5257774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,22]]},"references-count":94,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,12,22]]},"published-print":{"date-parts":[[2019,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izy376","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2018,12,22]]}}}